Merck & Co. (MRK) Shares Sold by Security National Trust Co.
Security National Trust Co. decreased its position in shares of Merck & Co. (NYSE:MRK) by 0.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 27,077 shares of the company’s stock after selling 100 shares during the period. Security National Trust Co.’s holdings in Merck & Co. were worth $1,560,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. Raymond James Trust N.A. increased its stake in shares of Merck & Co. by 3.3% in the second quarter. Raymond James Trust N.A. now owns 337,745 shares of the company’s stock worth $19,457,000 after buying an additional 10,865 shares during the period. Nordea Investment Management AB increased its stake in shares of Merck & Co. by 16.1% in the second quarter. Nordea Investment Management AB now owns 2,411,985 shares of the company’s stock worth $138,954,000 after buying an additional 334,806 shares during the period. Orbis Allan Gray Ltd bought a new stake in shares of Merck & Co. during the first quarter worth approximately $239,761,000. Envestnet Asset Management Inc. increased its stake in shares of Merck & Co. by 7.0% in the first quarter. Envestnet Asset Management Inc. now owns 1,107,242 shares of the company’s stock valued at $58,584,000 after buying an additional 72,808 shares during the period. Finally, Naples Global Advisors LLC increased its stake in shares of Merck & Co. by 3.9% in the second quarter. Naples Global Advisors LLC now owns 30,201 shares of the company’s stock valued at $1,740,000 after buying an additional 1,125 shares during the period. Institutional investors own 72.93% of the company’s stock.
Merck & Co. (NYSE:MRK) traded down 0.22% during midday trading on Thursday, reaching $62.66. 11,430,486 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $62.69 and a 200 day moving average price of $58.33. Merck & Co. has a 52 week low of $47.97 and a 52 week high of $64.00. The company has a market cap of $173.27 billion, a price-to-earnings ratio of 34.37 and a beta of 0.68.
Merck & Co. (NYSE:MRK) last issued its quarterly earnings results on Friday, July 29th. The company reported $0.93 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.91 by $0.02. Merck & Co. had a net margin of 13.01% and a return on equity of 23.41%. The company earned $9.84 billion during the quarter, compared to the consensus estimate of $9.79 billion. During the same quarter in the prior year, the firm posted $0.86 EPS. The firm’s quarterly revenue was up .6% on a year-over-year basis. Analysts anticipate that Merck & Co. will post $3.75 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 15th will be issued a dividend of $0.46 per share. This represents a $1.84 dividend on an annualized basis and a dividend yield of 2.94%. The ex-dividend date of this dividend is Tuesday, September 13th. Merck & Co.’s dividend payout ratio (DPR) is presently 101.10%.
Several analysts have issued reports on MRK shares. Vetr raised shares of Merck & Co. from a “sell” rating to a “buy” rating and set a $62.26 target price on the stock in a research note on Monday, July 4th. Argus reissued a “buy” rating on shares of Merck & Co. in a research note on Thursday, June 9th. Jefferies Group boosted their target price on shares of Merck & Co. from $50.00 to $53.00 and gave the company a “hold” rating in a research note on Thursday, July 14th. Leerink Swann reissued a “hold” rating and set a $58.00 target price on shares of Merck & Co. in a research note on Thursday, July 14th. Finally, Credit Suisse Group AG reissued a “hold” rating and set a $59.00 target price on shares of Merck & Co. in a research note on Wednesday, July 13th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of €63.20 ($70.23).
In other news, Chairman Kenneth C. Frazier sold 392,000 shares of the company’s stock in a transaction that occurred on Friday, August 5th. The shares were sold at an average price of €61.81 ($68.68), for a total transaction of €24,229,520.00 ($26,921,688.89). Following the completion of the sale, the chairman now owns 760,877 shares of the company’s stock, valued at approximately €47,029,807.37 ($52,255,341.52). The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Adam H. Schechter sold 39,200 shares of the company’s stock in a transaction that occurred on Thursday, September 1st. The stock was sold at an average price of €62.61 ($69.57), for a total transaction of €2,454,312.00 ($2,727,013.33). Following the sale, the executive vice president now directly owns 39,200 shares of the company’s stock, valued at approximately €2,454,312 ($2,727,013.33). The disclosure for this sale can be found here. Insiders own 0.05% of the company’s stock.
Merck & Co. Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.